Jacques Galipeau, MD close
Jacques Galipeau, MD

New Patients

Contact the Welcome Center for help choosing a new primary care doctor.

For Referring Physicians

How to refer a patient

Jacques Galipeau, MD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Dr. Galipeau is a board certified Hematologist with an interest in benign blood disorders, including diagnostic assessment of blood count and hematology laboratory abnormalities, congenital and acquired anemia, and autoimmune blood disorders.



Hematology (Leukemia, Lymphoma and Multiple Myeloma)

Hematology (non cancer)


UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map

UW School of Medicine and Public Health

Department of Medicine

Professional Certifications and Education

Board Certification Hematology

Hematology and Oncology, Tufts Medical Center, New England Medical Center Hospital, Boston, MA

Residency Jewish General Hospital, Montreal, Quebec, Canada
Internship Universite de Montreal, Montreal, Quebec, Canada
Medical School Universite de Montreal, Montreal, Quebec, Canada

Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.

Dr. Galipeau is the Don and Marilyn Anderson Professor of Oncology within the Department of Medicine and UW Carbone Comprehensive Cancer Center at the University of Wisconsin-Madison, and the inaugural Assistant Dean for Therapeutics Discovery and Development at the UW School of Medicine and Public Health. Dr. Galipeau has initiated and developed an NIH-funded research program in the study and use of mesenchymal stromal cells as an immunotherapy of catastrophic illnesses including cancer and immune disease. He is an internationally-recognized expert in translational development of cell therapies and the sponsor of a series of FDA-sanctioned clinical trials examining the use of autologous, marrow-derived mesenchymal stromal cells for immune disorders, including Crohn's disease and graft versus host disease. He has also developed the field of fusion engineered cytokines, known as fusokines, as a novel pharmaceutical means of treating immune disorders and cancer. He is the director of the University of Wisconsin Advanced Cell Therapy Program, whose mission is to develop personalized cell therapies for immune and malignant disorders and to promote and deploy first-in-human clinical trials of cell therapy innovations to improve outcomes for children and adults.

PubMed Articles
McCoy SS Giri J Das R Paul PK Pennati A Parker M Liang Y Galipeau J Minor salivary gland mesenchymal stromal cells derived from patients with SjÓ§gren's syndrome deploy intact immune plasticity. Cytotherapy . 2021 Apr;23(4):301-310
[PubMed ID: 33262072]
Galipeau J Macrophages at the nexus of mesenchymal stromal cell potency: The emerging role of chemokine cooperativity. Stem Cells . 2021 Mar 30;
[PubMed ID: 33786935]
Ramesha S Rayaprolu S Bowen CA Giver CR Bitarafan S Nguyen HM Gao T Chen MJ Nwabueze N Dammer EB Engstrom AK Xiao H Pennati A Seyfried NT Katz DJ Galipeau J Wulff H Waller EK Wood LB Levey AI Rangaraju S Unique molecular characteristics and microglial origin of Kv1.3 channel-positive brain myeloid cells in Alzheimer's disease. Proc Natl Acad Sci U S A . 2021 Mar 16;118(11)
[PubMed ID: 33649184]
Abney KK Galipeau J Aryl hydrocarbon receptor in mesenchymal stromal cells: new frontiers in AhR biology. FEBS J . 2020 Oct 16;
[PubMed ID: 33064873]
Pennati A Apfelbeck T Brounts S Galipeau J Washed Equine Platelet Extract as an Anti-Inflammatory Biologic Pharmaceutical. Tissue Eng Part A . 2020 Sep 30;
[PubMed ID: 32854583]
Galipeau J Luc Sensébé, champion of MSCs, dies. Cytotherapy . 2020 Sep;22(9):473
[PubMed ID: 32527642]
Pennati A Nylen EA Duncan ID Galipeau J Regulatory B Cells Normalize CNS Myeloid Cell Content in a Mouse Model of Multiple Sclerosis and Promote Oligodendrogenesis and Remyelination. J Neurosci . 2020 Jun 24;40(26):5105-5115
[PubMed ID: 32430295]
Giri J Galipeau J Mesenchymal stromal cell therapeutic potency is dependent upon viability, route of delivery, and immune match. Blood Adv . 2020 May 12;4(9):1987-1997
[PubMed ID: 32384543]
Galipeau J Mesenchymal Stromal Cells for Graft-versus-Host Disease: A Trilogy. Biol Blood Marrow Transplant . 2020 May;26(5):e89-e91
[PubMed ID: 32156632]
Nolta JA Galipeau J Phinney DG Improving mesenchymal stem/stromal cell potency and survival: Proceedings from the International Society of Cell Therapy (ISCT) MSC preconference held in May 2018, Palais des Congrès de Montréal, Organized by the ISCT MSC Scientific Committee. Cytotherapy . 2020 Mar;22(3):123-126
[PubMed ID: 32067856]
Giri J Das R Nylen E Chinnadurai R Galipeau J CCL2 and CXCL12 Derived from Mesenchymal Stromal Cells Cooperatively Polarize IL-10+ Tissue Macrophages to Mitigate Gut Injury. Cell Rep . 2020 Feb 11;30(6):1923-1934.e4
[PubMed ID: 32049021]
Chinnadurai R Rajakumar A Schneider AJ Bushman WA Hematti P Galipeau J Potency Analysis of Mesenchymal Stromal Cells Using a Phospho-STAT Matrix Loop Analytical Approach. Stem Cells . 2019 Aug;37(8):1119-1125
[PubMed ID: 31108008]
Chinnadurai R Sands J Rajan D Liu X Arafat D Das R Anania FA Gibson G Kisseleva T Galipeau J Molecular Genetic and Immune Functional Responses Distinguish Bone Marrow Mesenchymal Stromal Cells from Hepatic Stellate Cells. Stem Cells . 2019 Aug;37(8):1075-1082
[PubMed ID: 31033095]
Phinney DG Galipeau J MSC COMMITTEE OF THE INTERNATIONAL SOCIETY OF CELL AND GENE THERAPY. Manufacturing mesenchymal stromal cells for clinical applications: A survey of Good Manufacturing Practices at U.S. academic centers. Cytotherapy . 2019 Jul;21(7):782-792
[PubMed ID: 31182333]
Prasanphanich AF Johnson CT Krasnopeyev A Cantara S Roach C Gumber S Chinnadurai R Galipeau J Brewster L Prologo JD Image-Guided Transarterial Directed Delivery of Human Mesenchymal Stem Cells for Targeted Gastrointestinal Therapies in a Swine Model. J Vasc Interv Radiol . 2019 Jul;30(7):1128-1134.e5
[PubMed ID: 30852052]
Martin I Galipeau J Kessler C Le Blanc K Dazzi F Challenges for mesenchymal stromal cell therapies. Sci Transl Med . 2019 Feb 20;11(480)
[PubMed ID: 30787168]
Galipeau J Weiss DJ Dominici M Response to Nature commentary "Clear up this stem-cell mess". Cytotherapy . 2019 Jan;21(1):1-2
[PubMed ID: 30551850]
Chadid T Morris A Surowiec A Robinson S Sasaki M Galipeau J Pollack BP Brewster LP Reversible secretome and signaling defects in diabetic mesenchymal stem cells from peripheral arterial disease patients. J Vasc Surg . 2018 Dec;68(6S):137S-151S.e2
[PubMed ID: 30104096]
Zhang Z Wilson NA Chinnadurai R Panzer SE Redfield RR 3rd Reese SR Galipeau J Djamali A Autologous Mesenchymal Stromal Cells Prevent Transfusion-elicited Sensitization and Upregulate Transitional and Regulatory B Cells. Transplant Direct . 2018 Sep;4(9):e387
[PubMed ID: 30234156]
Pennati A Asress S Glass JD Galipeau J Adoptive transfer of IL-10<sup>+</sup> regulatory B cells decreases myeloid-derived macrophages in the central nervous system in a transgenic amyotrophic lateral sclerosis model. Cell Mol Immunol . 2018 Jul;15(7):727-730
[PubMed ID: 29307886]